|
|---|
|
Bruneau M Jr,
Milliron BJ,
Sinclair E,
Obeid E,
Gross L,
Bealin L,
Smaltz C,
Butryn M,
Giri VN. Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: a teachable moment for improved survivorship.
Support Care Cancer. 2021 Apr;29(4)
:2145-2151. PMC ID:PMC7897228. |
|
Mateo AM,
Mazor AM,
Obeid E,
Daly JM,
Sigurdson ER,
Handorf EA,
DeMora L,
Aggon AA,
Bleicher RJ. Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other Phenotypes.
Ann Surg Oncol. 2020 May;27(5)
:1679-1692. PMC ID:PMC7145740. |
|
Melchior NM,
Sachs DB,
Gauvin G,
Chang C,
Wang CE,
Sigurdson ER,
Daly JM,
Aggon AA,
Hayes SB,
Obeid EI,
Bleicher RJ. Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?.
Cancer Med. 2020 Feb 25;9(8)
:2742-2751. PMC ID:PMC7163083. |
|
Winn JS,
Hasse Z,
Slifker M,
Pei J,
Arisi-Fernandez SM,
Talarchek JN,
Obeid E,
Baldwin DA,
Gong Y,
Ross E,
Cristofanilli M,
Alpaugh RK,
Fernandez SV. Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer.
Int J Mol Sci. 2020 Feb 14;21(4)
. PMC ID:PMC7072950. |
|
Lynch SM,
Handorf E,
Sorice KA,
Blackman E,
Bealin L,
Giri VN,
Obeid E,
Ragin C,
Daly M. The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer.
PLoS One. 2020 ;15(8)
:e0237332. PMC ID:PMC7425919 . |
|
Page EC,
Bancroft EK,
Brook MN,
Assel M,
Hassan Al Battat M,
Thomas S,
Taylor N,
Chamberlain A,
Pope J,
Raghallaigh HN,
Evans DG,
Rothwell J,
Maehle L,
Grindedal EM,
James P,
Mascarenhas L,
McKinley J,
Side L,
Thomas T,
van Asperen C,
Vasen H,
Kiemeney LA,
Ringelberg J,
Jensen TD,
Osther PJS,
Helfand BT,
Genova E,
Oldenburg RA,
Cybulski C,
Wokolorczyk D,
Ong KR,
Huber C,
Lam J,
Taylor L,
Salinas M,
Feliubadalo L,
Oosterwijk JC,
van Zelst-Stams W,
Cook J,
Rosario DJ,
Domchek S,
Powers J,
Buys S,
O'Toole K,
Ausems Mgem,
Schmutzler RK,
Rhiem K,
Izatt L,
Tripathi V,
Teixeira MR,
Cardoso M,
Foulkes WD,
Aprikian A,
van Randeraad H,
Davidson R,
Longmuir M,
Ruijs MWG,
Helderman van den Enden Atjm,
Adank M,
Williams R,
Andrews L,
Murphy DG,
Halliday D,
Walker L,
Liljegren A,
Carlsson S,
Azzabi A,
Jobson I,
Morton C,
Shackleton K,
Snape K,
Hanson H,
Harris M,
Tischkowitz M,
Taylor A,
Kirk J,
Susman R,
Chen-Shtoyerman R,
Spigelman A,
Pachter N,
Ahmed M,
Ramon YCajal T,
Zgajnar J,
Brewer C,
Gadea N,
Brady AF,
van Os T,
Gallagher D,
Johannsson O,
Donaldson A,
Barwell J,
Nicolai N,
Friedman E,
Obeid E,
Greenhalgh L,
Murthy V,
Copakova L,
Saya S,
McGrath J,
Cooke P,
Ronlund K,
Richardson K,
Henderson A,
Teo SH,
Arun B,
Kast K,
Dias A,
Aaronson NK,
Ardern-Jones A,
Bangma CH,
Castro E,
Dearnaley D,
Eccles DM,
Tricker K,
Eyfjord J,
Falconer A,
Foster C,
Gronberg H,
Hamdy FC,
Stefansdottir V,
Khoo V,
Lindeman GJ,
Lubinski J,
Axcrona K,
Mikropoulos C,
Mitra A,
Moynihan C,
Rennert G,
Suri M,
Wilson P,
Dudderidge T,
Offman J,
Kote-Jarai Z,
Vickers A,
Lilja H,
Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Eur Urol. 2019 Sep 16;76(6)
:831-842. PMC ID:PMC6880781. |
|
West AH,
Knollman H,
Dugan J,
Hedeker D,
Handorf EA,
Nielsen SM,
Bealin LC,
Goldblatt LG,
Willems H,
Daly MB,
Afghahi A,
Olopade OI,
Hulick PJ,
Shagisultanova E,
Huo D,
Obeid E,
Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
Cancer Med. 2019 Aug 12;8(12)
:5609-5618. PMC ID:PMC6745828. |
|
Mateo AM,
Mazor AM,
DeMora L,
Sigurdson ER,
Handorf EA,
Daly JM,
Aggon AA,
Obeid E,
Hayes SB,
Bleicher RJ. Patterns of Care and Efficacy of Chemotherapy and Radiotherapy in Skin-Involved Breast Cancers of All Sizes.
Clin Breast Cancer. 2019 Aug;19(4)
:292-303. PMC ID:PMC6667298. |
|
Milliron BJ,
Bruneau M,
Obeid E,
Gross L,
Bealin L,
Smaltz C,
Giri VN. Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention.
Prostate. 2019 May;79(7)
:778-783. |
|
Guindalini RS,
Zheng YL,
Abe H,
Whitaker K,
Yoshimatsu TF,
Walsh T,
Schacht D,
Kulkarni K,
Sheth D,
Verp MS,
Bradbury AR,
Churpek J,
Obeid E,
Mueller J,
Khramtsova G,
Liu F,
Raoul A,
Cao HY,
Romero IL,
Hong S,
Livingston R,
Jaskowiak N,
Wang XM,
Debiasi M,
Pritchard CC,
King MC,
Karczmar G,
Newstead GM,
Huo D,
Olopade OI. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers.
Clin Cancer Res. 2019 Mar 15;25(6)
:1786-1794. PMC ID:PMC6395536. |
|
Giri VN,
Obeid E,
Hegarty SE,
Gross L,
Bealin L,
Hyatt C,
Fang CY,
Leader A. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
Prostate. 2018 Apr 14;78(12)
:879-888. PMC ID:PMC6047906. |
|
Heath EI,
Lynce F,
Xiu J,
Ellerbrock A,
Reddy SK,
Obeid E,
Liu SV,
Bollig-Fischer A,
Separovic D,
Vanderwalde A. Racial Disparities in the Molecular Landscape of Cancer.
Anticancer Res. 2018 Apr;38(4)
:2235-2240. PMC ID:PMC6123828. |
|
Giri VN,
Knudsen KE,
Kelly WK,
Abida W,
Andriole GL,
Bangma CH,
Bekelman JE,
Benson MC,
Blanco A,
Burnett A,
Catalona WJ,
Cooney KA,
Cooperberg M,
Crawford DE,
Den RB,
Dicker AP,
Eggener S,
Fleshner N,
Freedman ML,
Hamdy FC,
Hoffman-Censits J,
Hurwitz MD,
Hyatt C,
Isaacs WB,
Kane CJ,
Kantoff P,
Karnes RJ,
Karsh LI,
Klein EA,
Lin DW,
Loughlin KR,
Lu-Yao G,
Malkowicz SB,
Mann MJ,
Mark JR,
McCue PA,
Miner MM,
Morgan T,
Moul JW,
Myers RE,
Nielsen SM,
Obeid E,
Pavlovich CP,
Peiper SC,
Penson DF,
Petrylak D,
Pettaway CA,
Pilarski R,
Pinto PA,
Poage W,
Raj GV,
Rebbeck TR,
Robson ME,
Rosenberg MT,
Sandler H,
Sartor O,
Schaeffer E,
Schwartz GF,
Shahin MS,
Shore ND,
Shuch B,
Soule HR,
Tomlins SA,
Trabulsi EJ,
Uzzo R,
Vander Griend DJ,
Walsh PC,
Weil CJ,
Wender R,
Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
J Clin Oncol. 2018 Feb 1;36(4)
:414-424. PMC ID:PMC6075860. |
|
Mikropoulos C,
Selkirk CGH,
Saya S,
Bancroft E,
Vertosick E,
Dadaev T,
Brendler C,
Page E,
Dias A,
Evans DG,
Rothwell J,
Maehle L,
Axcrona K,
Richardson K,
Eccles D,
Jensen T,
Osther PJ,
van Asperen CJ,
Vasen H,
Kiemeney LA,
Ringelberg J,
Cybulski C,
Wokolorczyk D,
Hart R,
Glover W,
Lam J,
Taylor L,
Salinas M,
Feliubadalo L,
Oldenburg R,
Cremers R,
Verhaegh G,
van Zelst-Stams WA,
Oosterwijk JC,
Cook J,
Rosario DJ,
Buys SS,
Conner T,
Domchek S,
Powers J,
Ausems MG,
Teixeira MR,
Maia S,
Izatt L,
Schmutzler R,
Rhiem K,
Foulkes WD,
Boshari T,
Davidson R,
Ruijs M,
Helderman-van den Enden AT,
Andrews L,
Walker L,
Snape K,
Henderson A,
Jobson I,
Lindeman GJ,
Liljegren A,
Harris M,
Adank MA,
Kirk J,
Taylor A,
Susman R,
Chen-Shtoyerman R,
Pachter N,
Spigelman A,
Side L,
Zgajnar J,
Mora J,
Brewer C,
Gadea N,
Brady AF,
Gallagher D,
van Os T,
Donaldson A,
Stefansdottir V,
Barwell J,
James PA,
Murphy D,
Friedman E,
Nicolai N,
Greenhalgh L,
Obeid E,
Murthy V,
Copakova L,
McGrath J,
Teo SH,
Strom S,
Kast K,
Leongamornlert DA,
Chamberlain A,
Pope J,
Newlin AC,
Aaronson N,
Ardern-Jones A,
Bangma C,
Castro E,
Dearnaley D,
Eyfjord J,
Falconer A,
Foster CS,
Gronberg H,
Hamdy FC,
Johannsson O,
Khoo V,
Lubinski J,
Grindedal EM,
McKinley J,
Shackleton K,
Mitra AV,
Moynihan C,
Rennert G,
Suri M,
Tricker K,
Moss S,
Kote-Jarai Z,
Vickers A,
Lilja H,
Helfand BT,
Eeles RA. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Br J Cancer. 2018 Jan;118(2)
:266-276. PMC ID:PMC5785754. |
|
Hall MJ,
Forman AD,
Obeid E. The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste.
JAMA Oncol. 2017 Dec 1;3(12)
:1739-1740. |
|
Obeid EI,
Hall MJ,
Daly MB. Multigene Panel Testing and Breast Cancer Risk: Is It Time to Scale Down?.
JAMA Oncol. 2017 Sep 1;3(9)
:1176-1177. |
|
Hall MJ,
Obeid E,
Daly MB. Multigene Panels to Evaluate Hereditary Cancer Risk: Reckless or Relevant?.
J Clin Oncol. 2016 Dec;34(34)
:4186-4187. |
|
Roussi P,
Miller SM,
Giri VN,
Obeid E,
Wen KY,
Tagai EK,
Scarpato J,
Gross L,
Roy G. Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style.
J Health Psychol. 2016 Oct 1;23(14)
:1800-1809. PMC ID:PMC5561513. |
|
Hall MJ,
Obeid EI,
Schwartz SC,
Mantia-Smaldone G,
Forman AD,
Daly MB. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.
Gynecol Oncol. 2016 Mar;140(3)
:565-74. PMC ID:PMC4767686. |
|
Fleisher L,
Davis SN,
Gross L,
Bagden L,
Zakrzewski D,
Gonzalez E,
Kandadai V,
Rusten C,
Baskett J,
Obeid E,
Giri VN. Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project.
J Cancer Educ. 2016 Mar;31(1)
:191-7. |
|
Murphy CT,
Li T,
Wang LS,
Obeid EI,
Bleicher RJ,
Eastwick G,
Johnson ME,
Hayes SB,
Weiss SE,
Anderson PR. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
Clin Breast Cancer. 2015 Oct;15(5)
:381-9. |
|
Burness ML,
Obeid EI,
Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report.
Clin Breast Cancer. 2015 Apr;15(2)
:e155-8. |
|
Obeid E,
Nanda R,
Fu YX,
Olopade OI. The role of tumor-associated macrophages in breast cancer progression (review).
Int J Oncol. 2013 Jul;43(1)
:5-12. PMC ID:PMC3742164. |
|
Obeid E,
Nanda R,
Li T,
Zhang BF,
Mueller J,
Olopade OI. Association of downregulation of toll-like receptor 3 (TLR3) expression with aggressive breast cancer (BC).
Journal of Clinical Oncology. 2013 May;31(15)
. |
|
Guindalini RSC,
Huang YC,
Obeid E,
Patrick-Miller L,
Bradbury AR,
Verp MS,
Hong S,
Wroblewski K,
Abe H,
Karczmar GS,
Newstead G,
Olopade OI. Breast cancer survillance in high-risk women with magnetic resonance imaging every 6 months.
Journal of Clinical Oncology. 2013 May;31(15)
. |
|
Grushko TA,
Gomez-Vega MJ,
Prat A,
Mueller J,
Coyle M,
Perou CM,
Guindalini RSC,
Obeid E,
Irie H,
Olopade OI. Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+breast cancer as a mechanism of HER2 resistance.
Journal of Clinical Oncology. 2013 May;31(15)
. |
|
Abe H,
Guindalini RSC,
Obeid E,
Patrick-Miller LJ,
Bradbury AR,
Verp MS,
Hong S,
Wroblewski K,
Karczmar GS,
Newstead G,
Olopade OI. Recall rate in a semi-annual breast surveillance program for high-risk women.
Journal of Clinical Oncology. 2013 May;31(15)
. |
|
Obeid EI,
Conzen SD. The role of adrenergic signaling in breast cancer biology.
Cancer Biomark. 2013 ;13(3)
:161-9. |
|
Melhem-Bertrandt A,
Bojadzieva J,
Ready KJ,
Obeid E,
Liu DD,
Gutierrez-Barrera AM,
Litton JK,
Olopade OI,
Hortobagyi GN,
Strong LC,
Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
Cancer. 2012 Feb;118(4)
:908-913. |
|
Isaifan RJ,
Dole HAE,
Obeid E,
Lizarraga L,
Vernoux P,
Baranova EA. Metal-Support Interaction of Pt Nanoparticles with Ionically and Non-Ionically Conductive Supports for CO Oxidation.
Electrochemical and Solid State Letters. 2012 ;15(3)
:E14-E17. |
|
Faculty
Publications
